Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2017-01-09 Regulatory Filings
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX erhalt EUR 8,4 Millionen aus dem Bpifrance ,Programme d'Investissement d'avenir' (PIA) fur die Entwicklung innovativer antiviraler Wirkstoffe
Regulatory Filings Classification · 1% confidence The document is a press release dated January 9, 2017, announcing that ABIVAX received an EUR 8.4 million grant from the Bpifrance 'Programme d’Investissement d’avenir' (PIA) for developing antiviral drugs. It details funding amounts, project scope, and collaboration partners (CNRS). This type of announcement, focusing on receiving government/institutional funding or grants for R&D, fits best under 'Capital/Financing Update' (CAP), as it directly relates to securing capital/funding for operations and development, even if it's a grant rather than debt or equity issuance. It is not a formal regulatory report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA).
2017-01-09 German
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Regulatory Filings Classification · 1% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ AU 31 DECEMBRE 2016" (Semi-annual statement of the liquidity contract as of December 31, 2016). It details the holdings (shares and cash) under a liquidity contract, comparing the current period (Dec 31, 2016) to the previous period (June 30, 2016). This type of periodic disclosure related to market stabilization or liquidity provision is a specific regulatory requirement, often related to share trading or capital management. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR) which focuses on comprehensive P&L/Balance Sheet data. It is a specific update on capital/financing arrangements. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as it relates directly to the management of the company's share capital/liquidity provision mechanism, although 'Regulatory Filings' (RNS) could be a secondary fallback if CAP was deemed too broad. Since it is a specific report on a financing/liquidity contract, CAP is selected.
2017-01-09 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Capital/Financing Update Classification · 1% confidence The document is a press release dated January 9th, 2017, announcing that ABIVAX will receive €8.4 million in funding from Bpifrance's 'Invest in the Future Program' (PIA) to develop antiviral drugs. This is an announcement regarding financial support/funding for the company's R&D activities, which aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a transcript (CT). Since it details a specific financing event (receiving government/agency funding), CAP is the most appropriate classification.
2017-01-09 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Capital/Financing Update Classification · 1% confidence The document is a press release dated January 9, 2017, announcing that ABIVAX has secured 8.4 million euros in funding from the 'Programme d'investissement d'avenir (PIA)' via Bpifrance to support the development of innovative antiviral treatments. This announcement details a specific financing activity, including the amount, the source (government program/bank), and the purpose (R&D acceleration). This clearly aligns with the definition of 'Capital/Financing Update' (CAP), as it is a direct announcement regarding the company securing capital/funding for its operations and development pipeline.
2017-01-09 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French commercial code (article L. 233-8 II du code de commerce) and AMF regulations (article 223-16 du règlement général de l'Autorité des marchés financiers) for reporting share capital and voting rights as of a specific date (31/12/2016). This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement, often related to capital structure changes or general corporate status updates. While it relates to capital, it is not a general financing announcement (CAP) or a share issue/repurchase (SHA/POS). It is a specific regulatory disclosure about the current share count. Given the options, this specific disclosure about the total number of shares and voting rights, mandated by regulators, fits best under the general regulatory filing category, or potentially a specific capital/share related filing. Since there isn't a specific code for 'Share Capital Disclosure', and it is a formal regulatory update, 'RNS' (Regulatory Filings) is the most appropriate fallback for this specific, non-periodic financial report type. However, since the content is purely about the number of shares and voting rights, it is closely related to capital structure. Let's re-evaluate the options: SHA is 'Share Issue/Capital Change'. This document reports the *current* state, not an *announcement* of a change. Given the mandatory nature and specific regulatory citation, RNS is the safest general classification if a more specific one doesn't exist. If we consider the closest fit based on subject matter, it is about the share count, which is the basis for SHA. But SHA implies an *action* (issue/change). Since this is a routine disclosure of the current count, RNS is the best fit as a general regulatory filing.
2017-01-09 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Report Publication Announcement Classification · 1% confidence The document is a press release dated January 4, 2017, announcing that the CEO of ABIVAX will be presenting at the annual Biotech Showcase conference in San Francisco from January 9-11, 2017. This announcement details the time, location, and context of an upcoming investor/partner meeting, which is a common activity for companies seeking investment or partnerships. This type of announcement, focusing on participation in an industry conference to meet investors, aligns best with the Investor Presentation (IP) category, as it is essentially an announcement about an upcoming presentation to investors, or potentially a general Regulatory Filing (RNS) if no other category fits perfectly. Given the context of presenting company information (pipeline, strategy) at a major investor conference (Biotech Showcase, parallel to J.P. Morgan), it is most closely related to investor outreach materials. However, since it is an *announcement* of participation rather than the presentation itself, and it doesn't fit the specific definitions for ER, DIV, or CAP, the most appropriate classification among the provided options for an announcement related to investor engagement and company updates outside of formal reporting periods is often the general Regulatory Filing (RNS) or potentially Investor Presentation (IP) if we interpret the announcement as a proxy for investor communication. Given the focus on meeting investors and presenting the company, 'IP' (Investor Presentation) is a strong candidate, but 'RNS' (Regulatory Filings) is the safest fallback for general press releases about corporate events. Since the content is about an upcoming presentation at an investor conference, which is a key investor relations activity, I will classify it as 'IP' as it directly relates to investor communication strategy, even though it's an announcement of the event.
2017-01-04 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.